Alterations in gene expression in human umbilical cord blood CD34+ hematopoietic progenitor cells after lentiviral vector transduction
Keywords:
lentiviral vector, genetic modification, umbilical cord blood CD34 cells, integration sites, differential gene expressionAbstract
Aim: Transplantation of genetically modified human umbilical cord blood (UCB)-derived CD34+ hematopoietic stem/progenitor cells has emerged as a promising therapy for various malignant and non-malignant hematologic disorders. In turn, lentiviral vectors have been considered as suitable gene delivery vehicles for hematopoietic progenitor cells. However, their safety/risk profiles need to be further assessed. This study aimed to analyze the proviral-genomic integration sites and gene expression in human UCB-derived CD34+ cells transduced with a third generation HIV-1-based, vesicular stomatitis virus G glycoprotein-pseudotyped, GFP-tagged self-inactivating lentiviral vector. Materials and Methods: CD34+ cells, isolated from UCB of healthy full-term newborns, were transduced with the lentiviral vector. Proviral-genomic integration sites were analyzed by linear amplification-mediated polymerase chain reaction and DNA sequencing. Differential gene expression was analyzed by cDNA microarray. Results: Seven integration sites were identified. Two genes were up-regulated and six down-regulated, all by more than 2-fold, in the lentiviral vector-transduced CD34+ cells. The two up-regulated genes were IGSF4 (ImmunoGlobin Super Family member 4) and HEC (Highly Expressed in Cancer, rich in leucine heptad repeats), which are involved in leukemia and cell division. Conclusions: Given the importance of some of the differentially expressed genes detected in this study, the safety/risk profiles of lentiviral vectors as gene delivery vehicles for UCB-derived hematopoietic stem/progenitor cells warrant particular attention and further investigations.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.